NASDAQ · STOK
Stoke Therapeutics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarThe next earnings date for STOK has not been announced yet.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Dec 2026 | $-0.93 | $-0.81 | $-1.01 | 4 |
| Mar 2027 | $-0.96 | $-0.96 | $-0.96 | 1 |
| Jun 2027 | $-0.88 | $-0.88 | $-0.88 | 1 |
| Sep 2027 | $-0.89 | $-0.89 | $-0.89 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Fintel · Zacks · RTTNews · MarketBeat- Fintel · Oct 29, 11:02 PM EDTStoke Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business UpdatesStoke Therapeutics, Inc. reported its financial results for the third quarter ended September 30, 2026, and provided updates on its clinical programs. The company had $358.8 million in cash, cash equivalents and marketable securities as of September 30, 2026, which is expected to
- Zacks · Oct 29, 6:05 PM EDTStoke Therapeutics, Inc. (STOK) Reports Q3 Loss, Tops Revenue EstimatesStoke Therapeutics (STOK) delivered earnings and revenue surprises of -22.73% and +35.88%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
- RTTNews · Sep 4, 10:09 AM EDTWeekly Buzz: IONS, MIST, BIIB, AZN Win Nods; TCRX, NVS Cut Jobs; OVID, VIR Data; REGN, PASG Deals(RTTNews) – This week's biotech roundup saw a flurry of FDA and EU approvals across neurology, oncology, cardiology, and rare diseases, alongside new partnerships, trial readouts, and restructuring moves. Ionis, Milestone, Novavax advanced key programs, while United Imaging gaine
- RTTNews · Sep 4, 2:53 AM EDTStoke And Biogen Unveil Long-Term Zorevunersen Data In Dravet Syndrome(RTTNews) – Stoke Therapeutics, Inc. (STOK) and Biogen Inc. (BIIB) announced new long-term findings of zorevunersen in patients with Dravet syndrome, which will be presented at the 16th European Epilepsy Congress in Athens, Greece.
- RTTNews · Sep 1, 8:50 AM EDTBiogen: 4-year Data Support Potential Disease-modifying Effects Of Zorevunersen(RTTNews) – Stoke Therapeutics (STOK) and Biogen (BIIB) announced presentations of data at the 16th European Epilepsy Congress. The data support the potential of zorevunersen as a disease-modifying treatment for Dravet syndrome.
- MarketBeat · Aug 17, 8:01 PM EDTStoke Therapeutics’ Dravet Trial Tops Enrollment Target With Zero DropoutsStoke Therapeutics (NASDAQ:STOK) said its Phase III EMPEROR study of zorevunersen for Dravet syndrome has enrolled 162 patients, exceeding its target enrollment of 150, with no patient discontinuations reported to date. Speaking at a Canaccord Genuity event, Chief Executive Offi
- The Motley Fool · Aug 10, 9:58 PM EDTStoke Therapeutics (STOK) Q2 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- MarketBeat · Aug 3, 6:03 PM EDTStoke Therapeutics Q2 Earnings Call HighlightsStoke Therapeutics (NASDAQ:STOK) said its Phase III EMPEROR study of zorevunersen in patients with Dravet syndrome remains on track for a data readout in the third quarter of 2027, following completion of enrollment ahead of the company’s planned rolling new drug application subm
- Zacks · Aug 3, 5:10 PM EDTStoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue EstimatesStoke Therapeutics (STOK) delivered earnings and revenue surprises of -13.42% and +69.55%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Jul 14, 10:04 AM EDTIonis Begins Dosing in Phase I/II Dravet Syndrome StudyIONS doses first patient in the phase I/II ASCEND study of ION337, marking a key step in developing a potential disease-modifying treatment for Dravet syndrome.
- Zacks · Jun 5, 10:54 AM EDT4 Biotech Stocks Investors Should Watch in 2026New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position LQDA, IMNM, STOK and IMCR well in this volatile sector.
- Zacks · Jun 4, 9:55 AM EDTStoke Therapeutics (STOK) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?Stoke Therapeutics (STOK) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Stoke Therapeutics, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.